Recombinant VEGF (Aflibercept Biosimilar) antibody
Reactivity: Human
ELISA, SDS, WB
Host: Humanized
Monoclonal
Abz774
unconjugated
Recombinant Antibody
-
- Target
- VEGF (Aflibercept Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Humanized
- Expression System
- CHO Cells
-
Clonality
- Monoclonal
-
Conjugate
- This VEGF (Aflibercept Biosimilar) antibody is un-conjugated
- Application
- ELISA, SDS-PAGE (SDS), Western Blotting (WB)
- Purpose
- Recombinant Human VEGF receptor fused to a human IgG1 Fc fragment (Biosimilar of Aflibercept)
- Characteristics
- Biosimilar of Aflibercept, Eylea, Zaltrap, Vascular endothelial growth factor A, VEGF A, VEGFA, Vascular permeability factor, VPF
- Purification
- Recombinant VEGF receptor, Biosimilar of Aflibercept, was expressed in CHO cells.
- Purity
- The purity was estimated to be >90 % by SDS-PAGE analysis.
- Sterility
- Sterile filtered
- Clone
- Abz774
- Isotype
- IgG1
-
-
- Application Notes
- Application Note: Humanized Recombinant Human VEGF receptor has been tested for use in Western Blot and ELISA. This recombinant receptor recognizes structured VEGF-A and will work in western blot when the protein has not been denatured with DTT or bMe. This receptor is also cross-reactive with respective rabbit and murine VEGF. Although not tested, this receptor could be useful in Flow Cytometry and IHC and in in-vivo and other cellular assays. Specific conditions for reactivity should be optimized by the end user. Western Blot Dilution: 1 μg/mL ELISA Dilution: User Optimized
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1.0 mg/mL
- Buffer
-
Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Stabilizer: None
Preservative: 0.01 % (w/v) Sodium Azide - Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C
- Storage Comment
- Store vial at 2-8° C. Dilute only prior to immediate use.
- Expiry Date
- 6 months
-
- Target
- VEGF (Aflibercept Biosimilar)
- Background
- VEGF is a potent mitogen in embryonic and somatic angiogenesis with specificity for vascular endothelial cells. VEGF forms homodimers and exists in four different isoforms. Overall, the VEGF monomer resembles that of PDGF, but its N-terminal segment is helical rather than extended. VEGF shares homologies of about 21 % and 24 % respectively with the A and B chains of human platelet-derived growth factor (PDGF), and has complete conservation of the eight cysteine residues found in both mature PDGF chains. The cysteine knot motif is a common feature of this domain. The homology is not reflected in function, however, since the cell types responsive to VEGF are distinct from those responsive to homo- and heterodimers of the PDGF chains. This protein is a glycosylated mitogen that acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. VEGF-A also has been shown to have effects on a number of other cell types (e.g. stimulation of monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells). VEGF-A is also a vasodilator, it increases microvascular permeability, and was originally referred to as vascular permeability factor. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Aflibercept, known as EYLEA or ZALTRAP, is a recombinant fusion protein, consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and placental growth factor (PlGF) and thereby can inhibit the binding and activation of their cognate VEGF receptors. Aflibercept is a medication used to treat wet macular degeneration and metastatic colorectal cancer.
- UniProt
- P15692
-
You are here:
